MCID: LNG031
MIFTS: 52

Lung Benign Neoplasm

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Lung Benign Neoplasm

MalaCards integrated aliases for Lung Benign Neoplasm:

Name: Lung Benign Neoplasm 12 15
Lung Neoplasms 44 72
Tumor of the Lung 12
Lung Tumor 55

Classifications:



External Ids:

Disease Ontology 12 DOID:3683
MeSH 44 D008175
NCIt 50 C3200
UMLS 72 C0024121

Summaries for Lung Benign Neoplasm

MalaCards based summary : Lung Benign Neoplasm, also known as lung neoplasms, is related to glomus tumor and mucinous adenocarcinoma, and has symptoms including hemoptysis An important gene associated with Lung Benign Neoplasm is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Terbutaline and Ipratropium have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and testes, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Lung Benign Neoplasm

Diseases related to Lung Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 690)
# Related Disease Score Top Affiliating Genes
1 glomus tumor 30.7 TP53 SYP ENO2
2 mucinous adenocarcinoma 30.6 NKX2-1 KRT7 KRAS EGFR
3 mucoepidermoid carcinoma 30.6 KRT7 EGFR CHGA
4 exanthem 30.5 KRAS HRAS EGFR
5 adenoid cystic carcinoma 30.4 TP53 KRT7 KRAS HRAS
6 rhabdoid cancer 30.4 TP53 SYP ENO2
7 papillary adenocarcinoma 30.4 TP53 NKX2-1 KRT7
8 epithelial-myoepithelial carcinoma 30.4 TP53 KRT7 HRAS
9 thymoma 30.2 TP53 NKX2-1 HRAS EGFR
10 carcinosarcoma 30.2 TP53 KRT7 KRAS HRAS
11 recurrent respiratory papillomatosis 30.2 TP53 EGFR
12 cystadenoma 30.2 SYP KRT7 CHGA
13 carcinoid tumors, intestinal 30.1 SYP NKX2-1 ENO2 CHGA
14 alveoli adenoma 30.1 SCGB1A1 NKX2-1 KRT7 KRAS
15 ependymoma 30.1 SYP ENO2 EGFR
16 pulmonary large cell neuroendocrine carcinoma 30.0 SYP ENO2 CHGA
17 respiratory failure 30.0 SFTPC SFTPB SCGB1A1 NKX2-1
18 carcinoid syndrome 30.0 SYP ENO2 CHGA
19 basaloid squamous cell carcinoma 30.0 TP53 SYP KRT7 ENO2 EGFR
20 hemangioma of lung 30.0 SFTPB NKX2-1
21 lung squamous cell carcinoma 30.0 TP53 KRAS HRAS EGFR
22 intrahepatic cholangiocarcinoma 29.9 TP53 KRT7 KRAS EGFR
23 sweat gland cancer 29.9 TP53 SYP KRT7 ENO2
24 paraganglioma 29.9 SYP ENO2 CHGA
25 malignant pheochromocytoma 29.9 SYP ENO2 CHGA
26 pulmonary sclerosing hemangioma 29.8 SYP SFTPB NKX2-1 KRT7 CHGA
27 adenosquamous carcinoma 29.8 TP53 NKX2-1 KRT7 KRAS EGFR
28 renal cell carcinoma, nonpapillary 29.8 NKX2-1 KRT7 FHIT EGFR
29 newborn respiratory distress syndrome 29.8 SFTPC SFTPB SCGB1A1
30 myeloma, multiple 29.8 TP53 NCAM1 KRAS HRAS
31 sclerosing hemangioma 29.8 SYP SFTPB NKX2-1 KRT7 CHGA
32 interstitial lung disease 29.8 SFTPC SFTPB NKX2-1 EGFR
33 lung oat cell carcinoma 29.7 ENO2 CHGA
34 colorectal adenocarcinoma 29.7 TP53 KRT7 KRAS HRAS EGFR
35 pulmonary blastoma 29.7 TP53 SYP NKX2-1 KRAS EGFR CHGA
36 adenocarcinoma 29.7 TP53 RAF1 KRAS HRAS EGFR
37 large cell neuroendocrine carcinoma 29.7 SYP NKX2-1 NCAM1 KRT7 ENO2 EGFR
38 ganglioglioma 29.6 TP53 SYP ENO2 CHGA
39 teratoma 29.6 TP53 SYP NKX2-1 KRT7 ENO2
40 hemangioma 29.6 SYP SFTPB NKX2-1 KRAS ENO2 CHGA
41 lung disease 29.6 SFTPC SFTPB NKX2-1 GRP EGFR
42 meningioma, familial 29.6 TP53 SYP ENO2
43 larynx cancer 29.5 TP53 FHIT EGFR
44 bronchiolo-alveolar adenocarcinoma 29.5 NKX2-1 KRT7 KRAS FHIT EGFR
45 malignant mesenchymoma 29.5 TP53 NCAM1 FHIT
46 transitional cell carcinoma 29.4 TP53 KRT7 HRAS ENO2 EGFR
47 suppression of tumorigenicity 12 29.4 TP53 HRAS GRP CHGA
48 squamous cell carcinoma, head and neck 29.3 TP53 HRAS FHIT EGFR
49 small cell carcinoma 29.2 TP53 SYP NKX2-1 NCAM1 KRT7 ENO2
50 neuroendocrine tumor 29.2 SYP NKX2-1 NCAM1 KRT7 GRP ENO2

Graphical network of the top 20 diseases related to Lung Benign Neoplasm:



Diseases related to Lung Benign Neoplasm

Symptoms & Phenotypes for Lung Benign Neoplasm

UMLS symptoms related to Lung Benign Neoplasm:


hemoptysis

GenomeRNAi Phenotypes related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.91 EGFR HRAS KRAS NCAM1
2 Decreased viability GR00106-A-0 9.91 KRAS
3 Decreased viability GR00221-A-1 9.91 EGFR HRAS KRAS
4 Decreased viability GR00221-A-2 9.91 HRAS KRAS
5 Decreased viability GR00221-A-3 9.91 HRAS
6 Decreased viability GR00221-A-4 9.91 EGFR
7 Decreased viability GR00301-A 9.91 KRAS
8 Decreased viability GR00381-A-1 9.91 KRAS
9 Decreased viability GR00402-S-2 9.91 EGFR HRAS KRAS NCAM1
10 Increased cell migration GR00055-A-3 8.92 EGFR HRAS KRAS NCAM1

MGI Mouse Phenotypes related to Lung Benign Neoplasm:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.29 CADM1 ENO2 GRP HRAS KRAS NCAM1
2 homeostasis/metabolism MP:0005376 10.21 CHGA EGFR FHIT HRAS KRAS KRT7
3 growth/size/body region MP:0005378 10.2 CADM1 CHGA EGFR ENO2 HRAS KRAS
4 mortality/aging MP:0010768 10.18 CHGA EGFR FHIT HRAS KRAS NCAM1
5 cardiovascular system MP:0005385 10.15 CHGA EGFR HRAS KRAS NKX2-1 PTGIS
6 endocrine/exocrine gland MP:0005379 10.13 CADM1 CHGA EGFR HRAS KRAS NKX2-1
7 nervous system MP:0003631 10.1 CADM1 CHGA EGFR ENO2 GRP HRAS
8 neoplasm MP:0002006 10.02 EGFR FHIT HRAS KRAS NKX2-1 RAF1
9 no phenotypic analysis MP:0003012 9.86 CHGA EGFR HRAS KRAS NKX2-1 RAF1
10 normal MP:0002873 9.81 CADM1 EGFR HRAS KRAS NKX2-1 RAF1
11 renal/urinary system MP:0005367 9.56 CHGA EGFR HRAS KRAS KRT7 PTGIS
12 respiratory system MP:0005388 9.32 EGFR ENO2 HRAS KRAS NKX2-1 RAF1

Drugs & Therapeutics for Lung Benign Neoplasm

Drugs for Lung Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 747)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Terbutaline Approved Phase 4 23031-25-6 5403
2
Ipratropium Approved, Experimental Phase 4 60205-81-4, 22254-24-6 657309 43232
3
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
4
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
5
Dalteparin Approved Phase 4 9005-49-6
6
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
7
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
8
Remifentanil Approved Phase 4 132875-61-7 60815
9
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
10
Desflurane Approved Phase 4 57041-67-5 42113
11
Tropisetron Approved, Investigational Phase 4 105826-92-4, 89565-68-4 5595
12
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
13
Acetaminophen Approved Phase 4 103-90-2 1983
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
15
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
16
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
17
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
18
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
19
Imidacloprid Vet_approved Phase 4 105827-78-9 86418
20 Endostar protein Phase 4
21 Adrenergic alpha-2 Receptor Agonists Phase 4
22 Opiate Alkaloids Phase 4
23 Heparin, Low-Molecular-Weight Phase 4
24 calcium heparin Phase 4
25 Anesthetics, Intravenous Phase 4
26 Excitatory Amino Acid Antagonists Phase 4
27 Anesthetics, Dissociative Phase 4
28 Anesthetics, General Phase 4
29 Excitatory Amino Acids Phase 4
30 Free Radical Scavengers Phase 4
31 Diphosphonates Phase 4
32 Antidotes Phase 4
33 N-Methylaspartate Phase 4
34 alanine Phase 4
35
Bilirubin Phase 4 635-65-4, 69853-43-6 5280352 21252250
36 N-monoacetylcystine Phase 4
37 Serotonin Agents Phase 4
38 Serotonin Antagonists Phase 4
39 Serotonin 5-HT3 Receptor Antagonists Phase 4
40 Serotonin Uptake Inhibitors Phase 4
41 Antipsychotic Agents Phase 4
42 Anesthetics, Local Phase 4
43 Narcotics Phase 4
44 Antibodies Phase 4
45 Immunoglobulins Phase 4
46
Apatinib Phase 4 811803-05-1
47 Anti-Inflammatory Agents Phase 4
48 Hormones Phase 4
49 Hormone Antagonists Phase 4
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 4885)
# Name Status NCT ID Phase Drugs
1 The Exploratory Clinical Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin (Endostar) for Local Advanced Non-small Cell Lung Cancer (NSCLC (Ⅲ A / Ⅲ B) ) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
2 A Randomized ,Opened, Prospective Controlled Trial of Clinical Effectiveness for Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
3 A Study of Endostar in Combination With Chemotherapy Followed by Endostar Maintenance Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4 Endostar;Gemcitabine-Cisplatin chemotherapy
4 Efficacy of Nebulized Pulmicort Respules on Post Operation Pulmonary Complication During Pulmonary Single Lobectomy Surgery in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
5 A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4 Yangzhengxiaoji Capsule;Placebo Capsule
6 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
7 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer: a Multi-center, Randomized, Open Label Study Unknown status NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
8 The Randomized Controlled Clinical Trial of Kushen Injection Reducing Radiotherapy Related Adverse Reactions in Lung Cancer Unknown status NCT02346318 Phase 4 Compound Kushen Injection
9 Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients Unknown status NCT02275702 Phase 4 Dexamethasone IV;Saline solution
10 Safety Evaluation of Dexmedetomidine Monitored Anesthesia Care for Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
11 Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin Unknown status NCT01336192 Phase 4 Gemcitabine;Best supportive care
12 Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Unknown status NCT02513355 Phase 4 Changchun marina;cisplatin;Taxol;parapl
13 Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
14 PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
15 A Double-blind, Randomized, Placebo-controlled Study to Compare the Effectiveness of IV Acetaminophen Administered Intra-operatively in Reducing the Use of Opiates to Treat Post-operative Pain Completed NCT01783236 Phase 4 IV Acetaminophen;Saline Placebo
16 A Single Arm, Open Label, Perspective Study to Determine the Efficacy and Safety of Icotinib Combine Cryotherapy for Advanced NSCLC Patients Completed NCT02744664 Phase 4 Icotinib
17 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
18 A Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Completed NCT01287754 Phase 4 erlotinib [Tarceva]
19 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4 erlotinib [Tarceva]
20 A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
21 A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA®) as a Second-line Therapy in NSCLC Patients Completed NCT00608868 Phase 4 Gefitinib
22 An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer Completed NCT00949910 Phase 4 Erlotinib
23 A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
24 A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan Completed NCT01196078 Phase 4 erlotinib [Tarceva];vinorelbine
25 Post-marketing Clinical Trial of Induction Chemotherapy of Pemetrexed Plus Carboplatin Followed by Pemetrexed Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer Completed NCT01020786 Phase 4 Pemetrexed;Carboplatin
26 An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa Completed NCT01000740 Phase 4
27 A Multi-centre, Open-label, Phase IV, Interventional Study to Evaluate the Efficacy of Erlotinib (Tarceva®) Following 4 Cycles of Platinum-based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy Completed NCT01230710 Phase 4 Erlotinib
28 Anesthesia in Flexible Bronchoscopy for Lung Cancer Diagnostic Completed NCT00440960 Phase 4 propofol;midazolam;alfentanil;lidocaine
29 Medical and Economic Evaluation of FORESEAL Versus the Current Therapeutic Approach (Stapling Alone or Associated With Tissue Sealant) in Terms of Air Leakage Duration After Lung Resection for Cancer. Completed NCT00925444 Phase 4
30 Effects of Different Doses of Methylprednisolone on Immunological Function and Postoperative Adverse Reaction of Patients After Radical Resection of Lung Cancer by Thoracoscope Completed NCT03393949 Phase 4 Methylprednisolone 1 mg•kg-1;Methylprednisolone 0.5mg•kg-1
31 A Study Of Cryospray Ablationtm Using Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung Completed NCT00747773 Phase 4
32 ONCOXIN® and Quality of Life in Cancer Patients in a Real World Setting Study Completed NCT03550482 Phase 4
33 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
34 A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (StageIIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who HaveNot Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy Completed NCT00770588 Phase 4 Gefitinib;Placebo
35 Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]
36 Evaluation of the Usefulness of DurogesicD-TRANS for Pain Treatment in Lung Cancer Patients Completed NCT01060137 Phase 4 fentanyl matrix
37 A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis Completed NCT00099541 Phase 4 zoledronic acid
38 "Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Terminal Patients With Primary Lung Cancer or Lung metastases-a Pilot Study Completed NCT00338481 Phase 4 Morphine p.o.;Morphine s.c.
39 Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients With Resected Non-small Cell Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
40 Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy Completed NCT00380718 Phase 4 pemetrexed
41 A Multi-centric, Open-label, Phase II Study Investigating the Combination of Afinitor With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced (Stage IV) Large Cell Lung Cancer With Neuroendocrine Differentiation (LC-NEC) Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
42 Clinical Study of Recombinant Human Endostatin Combined With NP Chemotherapy in the Treatment of Stage ⅢA Non Small Cell Lung Cancer Completed NCT02497118 Phase 4 Endostatin;Vinorelbine;Cisplatin
43 Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer - A Randomized, Controlled Trial Completed NCT01741506 Phase 4 Dalteparin (Fragmin®)
44 Phase IV Randomized Trial of Pemetrexed Followed by Docetaxel or in Reverse Sequence in Non-small-cell Lung Cancer Patients Failed Previous Chemotherapy Completed NCT01442909 Phase 4 Docetaxel and pemetrexed
45 Phase IV/II Open-label Study to Evaluate Prompt Response to Treatment With Cisplatin, Gemcitabine and Bevacizumab in Patients With Non-small Lung Cancer. Completed NCT02316327 Phase 4 gemcitabine, cisplatin and bevacizumab
46 Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration, Using Rapid On-site Cytological Evaluation, for the Diagnosis of Hilar/Mediastinal Enlarged Lymph Nodes: a Randomized Controlled Trial. Completed NCT01658280 Phase 4
47 Safety of Low Dose Intravenous Contrast 64 Multi-Detector Computed Tomography Scanning in Patients With Chronic Kidney Disease Completed NCT02476526 Phase 4 Low Volume iso-osmolar non-ionic radio contrast medium;Acetylcysteine Inhalation;Sodium Bicarbonate Solution
48 Phase IV Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin in Previously Untreated, Inoperable (Stage IIIa or IIIb) Non-small-cell Lung Cancer Completed NCT00686322 Phase 4 Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
49 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
50 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride

Search NIH Clinical Center for Lung Benign Neoplasm

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Carboplatin
Carmustine
Cholecalciferol
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Etoposide
etoposide phosphate
Ifosfamide
Lomustine
Methotrexate
Methotrexate Sodium
Paclitaxel
Procarbazine
Procarbazine Hydrochloride
Teniposide
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: lung neoplasms

Genetic Tests for Lung Benign Neoplasm

Anatomical Context for Lung Benign Neoplasm

MalaCards organs/tissues related to Lung Benign Neoplasm:

41
Lung, Brain, Testes, Breast, T Cells, Lymph Node, Bone

Publications for Lung Benign Neoplasm

Articles related to Lung Benign Neoplasm:

(show top 50) (show all 1144)
# Title Authors PMID Year
1
GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors. 9 38
19620839 2009
2
Genetic alterations in K-ras and p53 cancer genes in lung neoplasms from Swiss (CD-1) male mice exposed transplacentally to AZT. 9 38
16395694 2007
3
Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms. Clinicopathologic studies. 9 38
16506596 2006
4
Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. 9 38
15547185 2004
5
The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. 9 38
15084379 2004
6
Dysregulated secretoglobin expression in human lung cancers. 9 38
12826312 2003
7
[Molecular targetting therapy for non-small-cell lung neoplasms with EGF-R inhibitors]. 9 38
12652739 2003
8
Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. 9 38
10987260 2000
9
Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. 9 38
9476905 1998
10
Membrane-bound (MUC1) and secretory (MUC2, MUC3, and MUC4) mucin gene expression in human lung cancer. 9 38
8638091 1996
11
Analysis of K-ras, p53 and c-raf-1 mutations in beryllium-induced rat lung tumors. 9 38
7545909 1994
12
Expression of epidermal growth factor receptor in plutonium-239-induced lung neoplasms in dogs. 9 38
1313613 1992
13
[Usefulness of simultaneous antigenic determination of carcinoembryonic antigen (CEA), ferritin and orosomucoid levels in diagnosis of lung neoplasms]. 9 38
1843646 1991
14
Embolization of Chest Neoplasms: The Next Frontier in Interventional Oncology? 38
31435125 2019
15
Left Lung Neoplasms and Bilateral Pleural Effusion Combined Elevated Carcinoembryonic Antigen in Pleural Effusion with Negative Result of Thoracoscopy Pleural Biopsy Misdiagnosed as Lung Carcinoma Ultimately Confirmed Pulmonary Sarcomatoid Carcinoma by CT-guided Percutaneous Lung Biopsy: a Case Report and Literature Review. 38
31414757 2019
16
Percutaneous radiofrequency ablation using internally cooled wet electrodes for the treatment of patients with lung tumors. 38
31378896 2019
17
[Fluorescence Guided Sublobar Lung Resection by Using Three-dimensional Image Analysis and Transbronchial Instillation of Indocyanine Green]. 38
31296801 2019
18
MAMDA: Inferring microRNA-Disease associations with manifold alignment. 38
31154259 2019
19
Prediction of Potential Disease-Associated MicroRNAs by Using Neural Networks. 38
31077936 2019
20
Bronchial Carcinoid Tumors with Massive Osseous Metaplasia: A Case Report and Review of the Literature. 38
30977863 2019
21
Surgical Treatment of Bilateral Lung Cancers: Long-Term Outcomes and Prognostic Factors. 38
30991418 2019
22
An integrated framework for the identification of potential miRNA-disease association based on novel negative samples extraction strategy. 38
30646823 2019
23
Inferring microRNA-disease association by hybrid recommendation algorithm and unbalanced bi-random walk on heterogeneous network. 38
30792474 2019
24
Spontaneous Partial Regression of a Carcinoid Tumor: Radiology May Not Capture the Real Picture. 38
30958990 2019
25
Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections. 38
30154579 2019
26
Metachronous Pulmonary Neoplasms in Lung Transplantation-When They Arise in the Donor Lung: A Case Report. 38
30577319 2018
27
Novel Human miRNA-Disease Association Inference Based on Random Forest. 38
30439645 2018
28
Prediction of potential disease-associated microRNAs by composite network based inference. 38
30361693 2018
29
Inferring disease-associated microRNAs in heterogeneous networks with node attributes. 38
30281474 2018
30
Diagnosis of Multiple Primary Intestinal-Type Adenocarcinoma in the Lung by 18F-FDG PET/CT. 38
30004935 2018
31
CT-guided percutaneous radiofrequency ablation for lung neoplasms adjacent to the pericardium. 38
30032841 2018
32
MDHGI: Matrix Decomposition and Heterogeneous Graph Inference for miRNA-disease association prediction. 38
30142158 2018
33
A Smooth Esophageal Stricture Causing Dysphagia. 38
29637299 2018
34
Clinical and Histopathologic Correlates and Management Strategies for Inflammatory Myofibroblastic tumor of the lung. A case series and review of the literature. 38
29869302 2018
35
Paraneoplastic limbic encephalitis associated with lung cancer. 38
29717222 2018
36
Advances on systemic treatment for lung neuroendocrine neoplasms. 38
29862235 2018
37
Insulinoma-associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens. 38
29360191 2018
38
Management of acquired bronchopleural fistula due to chemical pneumonia. 38
29875593 2018
39
Prediction of microRNA-disease associations based on distance correlation set. 38
29665774 2018
40
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. 38
29455666 2018
41
Histomorphological and Immunohistochemical Analysis of Pleural Neoplasms. 38
30697290 2018
42
Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature. 38
30305940 2018
43
Primary Pulmonary Anaplastic Large Cell Lymphoma: A Rare Malignancy and Rare Cause of the Luftsichel Sign. 38
29854536 2018
44
Monoglyceride lipase gene knockout in mice leads to increased incidence of lung adenocarcinoma. 38
29348400 2018
45
Lung Neoplasms with Low F18-Fluorodeoxyglucose Avidity. 38
29157381 2018
46
Predicting microRNA-disease associations using bipartite local models and hubness-aware regression. 38
30196756 2018
47
Effect and Toxicity of Radiation Therapy in Selected Palliative Indications. 38
31035767 2018
48
A Novel Computational Method for the Identification of Potential miRNA-Disease Association Based on Symmetric Non-negative Matrix Factorization and Kronecker Regularized Least Square. 38
30186308 2018
49
Endotracheal Intubation and In-Hospital Mortality after Intracerebral Hemorrhage. 38
29898436 2018
50
A Rare Case of Penile Metastases as a Harbinger of Primary Pulmonary Adenosquamous Carcinoma. 38
29785317 2018

Variations for Lung Benign Neoplasm

Expression for Lung Benign Neoplasm

Search GEO for disease gene expression data for Lung Benign Neoplasm.

Pathways for Lung Benign Neoplasm

Pathways related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.85 TP53 RAF1 KRAS HRAS EGFR
2 12.82 TP53 RAF1 KRAS HRAS EGFR
3 12.75 TP53 RAF1 KRAS HRAS EGFR
4
Show member pathways
12.75 TP53 RAF1 KRAS HRAS EGFR
5
Show member pathways
12.66 TP53 RAF1 KRAS HRAS EGFR
6
Show member pathways
12.61 TP53 RAF1 KRAS HRAS FHIT EGFR
7
Show member pathways
12.53 TP53 RAF1 KRAS HRAS EGFR
8 12.49 TP53 RAF1 KRAS HRAS EGFR
9
Show member pathways
12.46 TP53 RAF1 KRAS HRAS EGFR
10
Show member pathways
12.42 TP53 KRAS HRAS EGFR
11
Show member pathways
12.39 RAF1 KRAS HRAS EGFR
12
Show member pathways
12.38 RAF1 KRAS HRAS EGFR
13
Show member pathways
12.38 RAF1 KRAS HRAS EGFR
14
Show member pathways
12.3 RAF1 PTGIS HRAS EGFR
15
Show member pathways
12.25 TP53 RAF1 KRAS HRAS
16
Show member pathways
12.21 RAF1 KRAS HRAS EGFR
17 12.17 RAF1 KRAS HRAS EGFR
18 12.16 TP53 RAF1 KRAS HRAS EGFR
19 12.15 TP53 RAF1 KRAS HRAS
20
Show member pathways
12.15 TP53 RAF1 KRAS HRAS
21
Show member pathways
12.13 TP53 RAF1 KRAS HRAS EGFR
22
Show member pathways
12.12 TP53 RAF1 KRAS HRAS
23
Show member pathways
12.11 RAF1 KRAS HRAS EGFR
24
Show member pathways
12.05 RAF1 KRAS HRAS EGFR
25
Show member pathways
12.02 TP53 KRAS HRAS EGFR
26 11.99 TP53 RAF1 KRAS HRAS EGFR
27 11.97 TP53 RAF1 KRAS HRAS
28 11.96 TP53 RAF1 KRAS HRAS
29 11.92 TP53 RAF1 HRAS
30 11.86 RAF1 KRAS HRAS EGFR
31
Show member pathways
11.79 RAF1 KRAS HRAS
32 11.74 RAF1 KRAS HRAS EGFR
33 11.7 RAF1 KRAS HRAS EGFR
34 11.7 TP53 RAF1 KRAS HRAS EGFR
35 11.68 TP53 RAF1 HRAS
36
Show member pathways
11.67 RAF1 KRAS HRAS
37 11.66 TP53 KRAS HRAS
38 11.62 RAF1 KRAS HRAS
39 11.59 KRAS HRAS EGFR
40 11.56 TP53 RAF1 KRAS HRAS
41 11.46 TP53 RAF1 HRAS
42 11.38 RAF1 KRAS HRAS EGFR
43 11.35 RAF1 KRAS HRAS EGFR
44 11.26 RAF1 KRAS HRAS EGFR
45 11.23 TP53 KRAS HRAS EGFR
46 11.22 TP53 RAF1 KRAS HRAS EGFR
47 11.17 RAF1 KRAS EGFR
48
Show member pathways
11.15 KRAS HRAS EGFR
49 11.04 RAF1 KRAS HRAS
50 10.95 RAF1 KRAS HRAS

GO Terms for Lung Benign Neoplasm

Cellular components related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 SFTPC SFTPB SCGB1A1 PTGIS GRP ENO2
2 lamellar body GO:0042599 9.16 SFTPC SFTPB
3 multivesicular body lumen GO:0097486 8.62 SFTPC SFTPB

Biological processes related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 Ras protein signal transduction GO:0007265 9.63 TP53 KRAS HRAS
2 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.58 RAF1 KRAS HRAS
3 positive regulation of protein phosphorylation GO:0001934 9.56 RAF1 KRAS HRAS EGFR
4 positive regulation of MAP kinase activity GO:0043406 9.54 KRAS HRAS EGFR
5 cerebral cortex cell migration GO:0021795 9.49 NKX2-1 EGFR
6 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.48 TP53 EGFR
7 positive regulation of execution phase of apoptosis GO:1900119 9.43 TP53 PTGIS
8 response to isolation stress GO:0035900 9.32 KRAS HRAS
9 positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway GO:1900738 9.16 GRP CHGA
10 regulation of long-term neuronal synaptic plasticity GO:0048169 9.13 SYP KRAS HRAS
11 MAPK cascade GO:0000165 9.02 RAF1 NCAM1 KRAS HRAS EGFR

Molecular functions related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.02 RAF1 KRAS HRAS FHIT EGFR

Sources for Lung Benign Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....